Search
for

    Sort by

    Research 91–120 of 1000+

    1. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature Journal of Dermatological Treatment · 2016 · 40 citations
    2. Janus Kinase Inhibitors - A next generation treatment in Dermatology Journal of Pakistan Association of Dermatologists · 2022
    3. Inhibidores de JAK: usos en dermatología. Parte 1: generalidades, aplicaciones en vitíligo y en alopecia areata Actas Dermo-Sifiliográficas · 2020 · 20 citations
    4. Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis Journal of Investigative Dermatology · 2014 · 185 citations
    5. Discovery and Optimization of Novel Pyridines as Highly Potent and Selective Glycogen Synthase Kinase 3 Inhibitors 2019
    6. Dual improvement of alopecia areata and immune thrombocytopenia with baricitinib: a case report Skin Health and Disease · 2025
    7. Effectiveness of Tofacitinib in Pre-adolescent Alopecia Areata: A Retrospective Case Series and Literature Review Acta dermato-venereologica · 2023
    8. Tofacitinib for the treatment of lichen planopilaris: A case series Dermatologic therapy · 2018 · 79 citations
    9. Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review Dermatology and therapy · 2023 · 1 citations
    10. Two Birds that Exclude Each Other: The Renbök Phenomenon 2014 · 2 citations
    11. Baricitinib for alopecia areata Journal of Pakistan Medical Association · 2023
    12. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers Experimental Dermatology · 2016 · 70 citations
    13. Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours European Journal of Cancer · 2011 · 22 citations
    14. A Promising Efficacy of Tofacitinib in an Adult Patient with Alopecia Areata International Journal of Trichology · 2023
    15. Two phase III trials of baricitinib for alopecia areata: a critically appraised research paper British Journal of Dermatology · 2022 · 5 citations
    16. The role of oclacitinib in the management of ischaemic dermatopathy in four dogs Veterinary dermatology · 2019 · 19 citations
    17. Tofacitinib for the treatment of alopecia areata in preadolescent children Journal of the American Academy of Dermatology · 2018 · 40 citations
    18. Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development Clinical Pharmacokinetics · 2023 · 6 citations
    19. Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data Dermatology and Therapy · 2023
    20. A Novel Hope for Alopecia Totalis Patients: Case Report Dubai medical journal · 2020
    21. New Treatments for Hair Loss Actas Dermo-Sifiliográficas · 2017 · 7 citations
    22. ISID1108 - Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata. 2023
    23. Alopecia areata: current concepts Wiener klinische Wochenschrift · 2026
    24. Delphi Consensus Statement on Treatment of Severe Alopecia Areata in US Adults JAMA Dermatology · 2026
    25. 504 A single-center retrospective study evaluating the efficacy of intravenous methylprednisolone pulse therapy for 113 patients with alopecia areata 2023
    26. Recent Insight on the Management of Lupus Erythematosus Alopecia Clinical, Cosmetic and Investigational Dermatology · 2021 · 3 citations
    27. Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis Clinical Cosmetic and Investigational Dermatology · 2026
    28. New Treatment Strategies in Management of Alopecia Areata: Review Article The Egyptian Journal of Hospital Medicine · 2023
    29. Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma Clinical cancer research · 2004 · 234 citations
    30. First drug for severe alopecia recommended by NICE could benefit 14,000 patients 2024